These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 19825804)

  • 1. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting.
    Schmidt MM; Wittrup KD
    Mol Cancer Ther; 2009 Oct; 8(10):2861-71. PubMed ID: 19825804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Size-Dependent EPR Effect of Polymeric Nanoparticles on Tumor Targeting.
    Kang H; Rho S; Stiles WR; Hu S; Baek Y; Hwang DW; Kashiwagi S; Kim MS; Choi HS
    Adv Healthc Mater; 2020 Jan; 9(1):e1901223. PubMed ID: 31794153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors.
    Sung C; Shockley TR; Morrison PF; Dvorak HF; Yarmush ML; Dedrick RL
    Cancer Res; 1992 Jan; 52(2):377-84. PubMed ID: 1728409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Size on Solid Tumor Disposition of Protein Therapeutics.
    Li Z; Li Y; Chang HP; Chang HY; Guo L; Shah DK
    Drug Metab Dispos; 2019 Oct; 47(10):1136-1145. PubMed ID: 31387870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the duration of intravenous drug administration on tumor uptake.
    Fouliard S; Chenel M; Marcucci F
    Front Oncol; 2013; 3():192. PubMed ID: 23898461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size.
    Zahnd C; Kawe M; Stumpp MT; de Pasquale C; Tamaskovic R; Nagy-Davidescu G; Dreier B; Schibli R; Binz HK; Waibel R; Plückthun A
    Cancer Res; 2010 Feb; 70(4):1595-605. PubMed ID: 20124480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of molecular weight and structural conformation of multivalent-based elastin-like polypeptides on tumor accumulation and tissue biodistribution.
    Sarangthem V; Seo BY; Yi A; Lee YJ; Cheon SH; Kim SK; Singh TD; Lee BH; Park RW
    Nanotheranostics; 2020; 4(2):57-70. PubMed ID: 32190533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Side-by-Side Comparison of Commonly Used Biomolecules That Differ in Size and Affinity on Tumor Uptake and Internalization.
    Leelawattanachai J; Kwon KW; Michael P; Ting R; Kim JY; Jin MM
    PLoS One; 2015; 10(4):e0124440. PubMed ID: 25901755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical theoretic guidance for the design of tumor-targeting agents.
    Wittrup KD; Thurber GM; Schmidt MM; Rhoden JJ
    Methods Enzymol; 2012; 503():255-68. PubMed ID: 22230572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor uptake of pegylated diabodies: Balancing systemic clearance and vascular transport.
    Li Q; White JB; Peterson NC; Rickert KW; Lloyd CO; Allen KL; Rosenthal K; Gao X; Wu H; Dall'Acqua WF; Borrok MJ; Tsui P
    J Control Release; 2018 Jun; 279():126-135. PubMed ID: 29653224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuning Ligand Density To Optimize Pharmacokinetics of Targeted Nanoparticles for Dual Protection against Tumor-Induced Bone Destruction.
    Vanderburgh J; Hill JL; Gupta MK; Kwakwa KA; Wang SK; Moyer K; Bedingfield SK; Merkel AR; d'Arcy R; Guelcher SA; Rhoades JA; Duvall CL
    ACS Nano; 2020 Jan; 14(1):311-327. PubMed ID: 31894963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform.
    Hou L; Shan X; Hao L; Feng Q; Zhang Z
    Acta Biomater; 2017 May; 54():307-320. PubMed ID: 28274767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer.
    Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC
    Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug.
    Lee BS; Park K; Park S; Kim GC; Kim HJ; Lee S; Kil H; Oh SJ; Chi D; Kim K; Choi K; Kwon IC; Kim SY
    J Control Release; 2010 Oct; 147(2):253-60. PubMed ID: 20624433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mechanistic compartmental model for total antibody uptake in tumors.
    Thurber GM; Dane Wittrup K
    J Theor Biol; 2012 Dec; 314():57-68. PubMed ID: 22974563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding.
    Sung C; Youle RJ; Dedrick RL
    Cancer Res; 1990 Nov; 50(22):7382-92. PubMed ID: 2224866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular imprinted S-nitrosothiols nanoparticles for nitric oxide control release as cancer target chemotherapy.
    Liu T; Qiao Z; Wang J; Zhang P; Zhang Z; Guo DS; Yang X
    Colloids Surf B Biointerfaces; 2019 Jan; 173():356-365. PubMed ID: 30316082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
    Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
    Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.